The researchers evaluated socioeconomic data from the 2011 Combining Medications to Enhance Depression Outcomes (CO-MED) study to ascertain whether social determinants affect treatment response in those with major depression.
Investigators searched publication databases through October 2021 for studies of drug-specific biomarkers for tricyclic antidepressant treatment response.
To examine the polypharmacy situation in children and adolescents, the researchers conducted a nationwide study of children and teens in Finland who had received an antipsychotic drug.
Researchers looked at whether patients with OCD, after achieving wellness, can taper to discontinuation of serotonin reuptake inhibitors (SRIs) and maintain decreased symptoms of obsessive-compulsive disorder (OCD).
In this investigation, researchers examined how patients with schizophrenia are represented in randomized clinical trials and questioned if the results are different for patients not represented in randomized clinical trials.
In order to evaluate the relationship of sleep disturbance to the antidepressant effects of esketamine, 2 double-blind, 4-week studies randomized adults with treatment-resistant depression (TRD) to placebo or esketamine nasal spray.
The researchers investigated the association of serotonin reuptake inhibitors with outcomes in patients with COVID-19 by analyzing electronic health records.
Despite prior suspicion, the review shows no link between dry eye disease and antidepressants or antihypertensives.
Researchers provided practical tips and management approach strategies for the treatment of severe irritable bowel syndrome.
Regular antidepressant use is associated with a lower risk for diabetes complications among adults with depression and newly treated diabetes.
